OKL-1111 / Alveron Pharma - LARVOL DELTA

First in-Human Study with Okl-1111, a Novel Small Molecule Universal Anticoagulant and Platelet Inhibitor Reversal Agent (ASH 2024) - "OKL-1111 reversed the action of a wide variety of anticoagulants (dabigatran, apixaban, rivaroxaban, edoxaban, warfarin, enoxaparin and fondaparinux) as well as platelet inhibitors (ticagrelor and clopidogrel) in vivo without any sign of thrombotic overshoot. OKL-1111 at a single dose of 1000mg reduced the dabigatran-induced lagtime increase in TGA. Discussion : OKL-1111, to our knowledge the first fully universal reversal agent and the only clopidogrel reversal agent, can be safely administered to volunteers up to 1000mg, without (serious) adverse events."

First-in-human • P1 data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Thrombosis

First in-Human Study with Okl-1111, a Novel Small Molecule Universal Anticoagulant and Platelet Inhibitor Reversal Agent (ASH 2024) - "OKL-1111 reversed the action of a wide variety of anticoagulants (dabigatran, apixaban, rivaroxaban, edoxaban, warfarin, enoxaparin and fondaparinux) as well as platelet inhibitors (ticagrelor and clopidogrel) in vivo without any sign of thrombotic overshoot. OKL-1111 at a single dose of 1000mg reduced the dabigatran-induced lagtime increase in TGA. Discussion : OKL-1111, to our knowledge the first fully universal reversal agent and the only clopidogrel reversal agent, can be safely administered to volunteers up to 1000mg, without (serious) adverse events."

First-in-human • P1 data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Thrombosis